OBJECTIVES: To examine the trends in the prescribing of subsidized proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs), in the Australian population from 1995 to 2006 to encourage discussion regarding appropriate clinical use. PPIs and H2RAs are the second highest drug cost to the publicly subsidized Pharmaceutical Benefits Scheme (PBS). DESIGN: Government data on numbers of subsidized scripts, quantity and doses for PPIs and H2RAs were analysed by gender and age, dose and indication. MAIN OUTCOME MEASURE: Drug utilisation as DDD [defined daily dose]/1000 population/day. RESULTS: The use of combined PPIs increased by 1318%. Utilisation increased substantially after the relaxation of the subsidized indications for PPIs in 2001. Omeprazole had the largest market share but was substituted by its S-enantiomer esomeprazole after its introduction in 2002. There was considerable use in the elderly with the peak use being in those aged 80 years and over. The utilisation of H2RAs declined 72% over 12 years. CONCLUSIONS: PPI use has increased substantially, not only due to substitution of H2RAs but to expansion in the overall market. Utilisation does not appear to be commensurate with prevalence of gastro-oesophageal reflux disease (GORD) nor with prescribing guidelines for PPIs, with significant financial costs to patients and PBS. This study encourages clinical discussion regarding quality use of these medicines.
OBJECTIVES: To examine the trends in the prescribing of subsidized proton pump inhibitors (PPIs) and histamine receptor antagonists (H2RAs), in the Australian population from 1995 to 2006 to encourage discussion regarding appropriate clinical use. PPIs and H2RAs are the second highest drug cost to the publicly subsidized Pharmaceutical Benefits Scheme (PBS). DESIGN: Government data on numbers of subsidized scripts, quantity and doses for PPIs and H2RAs were analysed by gender and age, dose and indication. MAIN OUTCOME MEASURE: Drug utilisation as DDD [defined daily dose]/1000 population/day. RESULTS: The use of combined PPIs increased by 1318%. Utilisation increased substantially after the relaxation of the subsidized indications for PPIs in 2001. Omeprazole had the largest market share but was substituted by its S-enantiomer esomeprazole after its introduction in 2002. There was considerable use in the elderly with the peak use being in those aged 80 years and over. The utilisation of H2RAs declined 72% over 12 years. CONCLUSIONS: PPI use has increased substantially, not only due to substitution of H2RAs but to expansion in the overall market. Utilisation does not appear to be commensurate with prevalence of gastro-oesophageal reflux disease (GORD) nor with prescribing guidelines for PPIs, with significant financial costs to patients and PBS. This study encourages clinical discussion regarding quality use of these medicines.
Authors: Hanifat Hamzat; Hao Sun; Joanna C Ford; Joan Macleod; Roy L Soiza; Arduino A Mangoni Journal: Drugs Aging Date: 2012-08-01 Impact factor: 3.923
Authors: Hojjat Salmasian; Daniel E Freedberg; Julian A Abrams; Carol Friedman Journal: Pharmacoepidemiol Drug Saf Date: 2012-12-12 Impact factor: 2.890
Authors: Magdalena Gómez-Mateos; Francisco Arrebola; María Concepción Navarro; María Carmen Romero; José María González; Adela Valero Journal: Dig Dis Sci Date: 2020-02-27 Impact factor: 3.199